Home > Dermatology > SPIN 2019 > Novel Considerations > ABP501 biosimilar for adalimumab: What you need to know

ABP501 biosimilar for adalimumab: What you need to know

Presented By
Prof. Brian Kirby, St Vincent's Hospital, Dublin, Ireland
SPIN 2019
Prof. Brian Kirby (St Vincent's Hospital, Dublin, Ireland) presented convincing data on the efficacy and safety of biosimilar ABP501 vs adalimumab in psoriasis patients [1]. Prof. Kirby began by reminding the audience that the development of targeted and effective biological therapies has transformed the outcomes for patients with psoriasis. Biosimilars are approved by regulatory authorities on the basis of rigorous clinical trials that demonstrate they are highly similar to the reference product in terms of quality, safety, and efficacy [2]. Minor differences in clinically inactive components must be supported by strong scientific evidence that these differences are not clinically meaningful. In general, they have lower acquisition costs than the reference product, and biosimilars have been shown to introduce price competition into the market, leading to reduced prices for the treatment of all patients [3]. Consequently, health authorities are increasing ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on